ClinicalTrials.gg
CompletedNCT01830660Updated Apr 6, 2015

A Phase I Study of Hetrombopag Olamine in Healthy Adult Volunteers

A Phase 1 interventional study of Hetrombopag Olamine Tablets and placebo in Healthy, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-04-06.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

Hetrombopag Olamine made by Jiangsu Hengrui Medicine co Ltd. has shown an effect of increasing platelet count in animal and human. This study is designed in dose escalation fashion to evaluate safety, pharmacokinetics and efficacy of Hetrombopag Olamine.

Read the detailed description
  1. To evaluate safety and tolerability of Hetrombopag Olamine.
  2. To investigate pharmacokinetics of Hetrombopag Olamine Under fasting conditions.
  3. To obtain pharmacodynamics information of Hetrombopag Olamine on platelet count elevation in healthy volunteers.
  4. To determine preliminary regimen for phase II study.
02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must be adequately informed of the nature and risks of the study, able to understand the risks associated with the study, and are willing to provide written prior to screening.
  2. Must be a healthy male between the ages of 18 to 45 years, inclusive.
  3. Must have a between 19 to 28 kg/m2, inclusive and a total body weight ≥50 kg.
  4. counts must be within the normal range.
  5. Subjects must be free of any disease based on medical history and physical examination.
  6. Clinical laboratory tests (complete blood count [CBC], blood chemistries, and urinalysis) must be within the normal limits or clinically acceptable.
  7. Must be nonsmokers, defined as not having smoked tobacco or used chewing tobacco or nicotine.
  8. Subjects of with partners who are women of , will be instructed to, and must be willing to practice a highly effective method of for the duration of the study and continuing 6 months after discontinuing treatment with the product.

Exclusion criteria

Exclusion Criteria:

  1. History of to hetrombopag olamine or its components.
  2. History or presence of significant cardiovascular deficient, pulmonary, hepatic, gallbladder or biliary tract, renal, hematological, gastrointestinal, endocrine, immunological, dermatological, neurological, or psychiatric disease, or any other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
  3. History of deep vein thrombosis, or any other thromboembolic event.
  4. History or presence of conditions that may place the subject at increased risk as determined by the investigator.
  5. History of thrombocytopenia or bleeding due to abnormal number or function.
  6. History of platelet clumping that prevents reliable measurement of platelet counts.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    hetrombopag

    hetrombopag either at 2.5,5,10,20,30 or 40mg, p.o. once daily

    Drug: Hetrombopag Olamine Tablets

  • Placebo comparator
    placebo

    Subjects will be randomized (5:1 eltrombopag : placebo) to receive either eltrombopag or placebo.

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in platelet count above baseline(%)on Day1,3,5,8,10,12,15,17,19,22,25,28 after dosing

    Time frame: up to 4 weeks

  2. Composite pharmacokinetic (PK) parameters of eltrombopag following a single dose of eltrombopag

    Time frame: For 5 days

Secondary outcomes

  1. Adverse events

    Time frame: up to 4 weeks

  2. Change in vital signs

    Time frame: up to 4 weeks

  3. Change in clinical laboratory parameters

    Time frame: up to 4 weeks

07

Study locations

1 site
  • West China Hospital, Sichuan University
    Chengdu, Sichuan, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 25, 2012
First posted
Apr 12, 2013
Start
Apr 2012
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Last update
Apr 6, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01830660
Responsible party
Sponsor
First posted
Apr 12, 2013
Start date
Apr 2012
Primary completion
Jun 2013
Completion
Jun 2013
Last update
Apr 6, 2015

Study contacts

Maozhi Liang, Dr
principal investigator · West China Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hetrombopag olamine

Start the discussion